Lisata Therapeutics: appoints director Jeffrey Farrow

What happened The company reported that on Oct 13, 2026 the board approved an increase in the size of the board from 7 to 8 members and appointed Jeffrey Farrow as a Class III member of the board, effective immediately, with an initial term expiring at the company's 2028 annual meeting of stockholders. The board also appointed Mr. Farrow as a member of the audit committee. On Oct 14, 2026 the company issued a press release announcing the appointment.

Key details

• Board size increased from 7 to 8; appointment effective Oct 13, 2026; initial term expires at the 2028 annual meeting.
• Jeffrey Farrow, Age 65, has served as chief financial officer and chief strategy officer of Tarsus Pharmaceuticals since Apr 2023 and has prior CFO and board roles at multiple biopharmaceutical companies.
• Mr. Farrow was appointed to the audit committee and has entered the company’s standard form of indemnification agreement.
• The board determined Mr. Farrow is an independent director; the company reported no family relationships, no selection arrangements with other persons, and no transactions requiring disclosure under Item 404(a).

Why it may matter This report was filed under Item 5.02 (Departure of directors or certain officers; election of directors), which covers changes to the company’s board and officers. A filing does not show why the insider traded or why the company acted.